Swiss National Bank’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Swiss National Bank’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-152,900	Closed	-$3.08M	–	2766
2021 Q3	$3.08M	Buy	152,900 +4,000	+3%	+$110K	﹤0.01%	1765
2021 Q2	$5.56M	Buy	148,900 +3,200	+2%	+$98.1K	﹤0.01%	1434
2021 Q1	$3.73M	Buy	145,700 +2,600	+2%	+$66.4K	﹤0.01%	1642
2020 Q4	$3.15M	Buy	143,100 +700	+0.5%	+$15.4K	﹤0.01%	1648
2020 Q3	$2.56M	Buy	142,400 +2,500	+2%	+$51.8K	﹤0.01%	1593
2020 Q2	$3.55M	Buy	139,900 +40,400	+41%	+$870K	﹤0.01%	1355
2020 Q1	$1.83M	Buy	99,500 +1,400	+1%	+$27.2K	﹤0.01%	1511
2019 Q4	$2.16M	Buy	98,100 +1,900	+2%	+$38.2K	﹤0.01%	1687
2019 Q3	$1.38M	Buy	96,200 +8,600	+10%	+$123K	﹤0.01%	1884
2019 Q2	$1.38M	Buy	87,600 +7,600	+10%	+$103K	﹤0.01%	1933
2019 Q1	$1.17M	Buy	80,000 +4,500	+6%	+$51.7K	﹤0.01%	1984
2018 Q4	$807K	Buy	75,500 +10,000	+15%	+$132K	﹤0.01%	2124
2018 Q3	$1M	Buy	65,500 +11,400	+21%	+$166K	﹤0.01%	2141
2018 Q2	$663K	Buy	+54,100	New	+$680K	﹤0.01%	2363

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Swiss National Bank's DRNA Position: Q4 2021 in Review

Swiss National Bank sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 152,900 shares — an estimated $3.08M sold.

Swiss National Bank first reported a position in DRNA in Q2 2018 and held it in 14 quarters. The position peaked at $5.56M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Swiss National Bank reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Swiss National Bank sold 152,900 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $3.08M.
Swiss National Bank first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2018 and held it in 14 quarters.
Swiss National Bank's Dicerna Pharmaceuticals, Inc. position peaked at $5.56M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Swiss National Bank's 13F filing for Q4 2021, filed 8 Feb 2022.